Competitive Generic Therapies: Off-Patent Drugs With 2 Sources
✉ Email this page to a colleague
This table lists drugs which, despite having no patents or regulatory protections, have a limited number of active sources.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Strength |
---|---|---|---|---|---|---|---|---|---|---|
Galephar | LEGUBETI | acetylcysteine lysine | FOR SOLUTION;ORAL | 215040-002 | Feb 13, 2024 | RX | Yes | Yes | EQ 2.5GM BASE/PACKET | |
Galephar | LEGUBETI | acetylcysteine lysine | FOR SOLUTION;ORAL | 215040-001 | Feb 13, 2024 | RX | Yes | Yes | EQ 500MG BASE/PACKET | |
Organon Llc | FOSAMAX PLUS D | alendronate sodium; cholecalciferol | TABLET;ORAL | 021762-001 | Apr 7, 2005 | RX | Yes | No | EQ 70MG BASE;2,800 IU | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Strength |